EDU 47 - Intersection of Immuno-Molecular-Genetic Profiling and Implications for Immunotherapy (IT) and Immunotherapy-Radiotherapy (IT-RT) Combinations

Moderator(s)

• 

  Ariel Marciscano, MD

  Massachusetts General Hospital
  Boston, Massachusetts, United States

Although immunotherapy has revolutionized the treatment of cancer, the translation of immunotherapy-radiotherapy (IT-RT) combinations into the clinic has proven challenging. While radiotherapy can be immuno-stimulatory, it also is known to have several immuno-suppressive properties that may be responsible for difficulty in clinical translation. To this end, the past decade has revealed mounting evidence that various germline mutations, somatic alterations and other tumor-intrinsic molecular features influence the immune contexture of the tumor microenvironment (TME) and thus the potential to modulate the interaction between immunotherapy and radiotherapy. In parallel, molecular-genetic tumor profiling and next-generation sequencing (NGS) are now standard-of-care across a spectrum of malignancies and are increasingly used for prognostication, refinement of treatment selection and monitoring of treatment response.

The goal of this session will be to review emerging molecular profiles of tumors that influence the interaction of radiotherapy with immunotherapy. In the era of personalized medicine, radiation oncologists should be familiar with immuno-molecular-genomic tumor profiling and how these assays and biomarkers may help identify subgroups of patients that are most likely to benefit from IT-RT combination strategies and help design future trials that enrich for potential responders.

Presentations:

• 2:30 PM – 2:32 PM ET

  Introductions
  

  Speaker: Ariel Marciscano, MD – Massachusetts General Hospital
• 2:32 PM – 2:44 PM ET

  The Intersection of Tumor-Intrinsic Genomics and Anti-Tumor Immunity: Preclinical and Clinical Insights
  

  Speaker: Jason Luke, MD – UPMC Hillman Cancer Center
• 2:44 PM – 2:56 PM ET

  Leveraging Molecular-Genetic-Epigenetic Characterization to Refine Patient and Treatment Selection for IT-RT Combinations
  

  Speaker: Sean Pitroda, MD – University of Chicago
• 2:56 PM – 3:08 PM ET

  Biologically-Guided Approaches to Address Intrinsic Resistance to IT-RT Combinations
  

  Speaker: Yvonne Mowery, MD, PhD, BS – University of Pittsburgh, UPMC Hillman Cancer Center
• 3:08 PM – 3:20 PM ET

  Integrating Radiation Oncology into an Era of Precision Medicine: Rationale Approaches for Future Personalized IT-RT Combinations
  

  Speaker: Nadeem Riaz, MD, MS – Memorial Sloan Kettering Cancer Center
• 3:20 PM – 3:35 PM ET

  Questions and Answers
  

  Speaker: Ariel Marciscano, MD – Massachusetts General Hospital